Study on the diagnostic and recurrence monitoring value of gene methylation detection reagents for urothelial carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500098915

Enrollment

Unknown

Registered

2025-03-14

Start date

2025-03-14

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma

Interventions

Gold Standard:Cystoscopy with biopsy and pathological examination

Index test:Methylation-specific detection kit

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years, regardless of gender. Patients with urothelial carcinoma scheduled to undergo cystoscopy; 2.no specific requirements for control group participants. Willingness to participate in the study and provision of voluntarily signed written informed consent.

Exclusion criteria

Exclusion criteria: 1.History of other malignancies. Subjects deemed by the investigator to be unsuitable for participation in this clinical trial. Subjects with incomplete medical records (including gender, age, diagnostic information, cystoscopy and/or pathological diagnosis results for urothelial carcinoma patients, and other demographic data, etc.); 2.control group patients are not required to have cystoscopy or pathological diagnosis results.

Design outcomes

Primary

Measure	Time frame
Detection of Urothelial Carcinoma;	—

Countries

China

Contacts

Public ContactJie Li

Lishui Central Hospital

lijie9783@126.com+86 15990848220

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026